Form 4: Baker Bros. Advisors LP Increases Stake in Bicycle Therapeutics PLC Through Multiple Transactions

Baker Bros. Advisors LP and related entities have increased their holdings in Bicycle Therapeutics PLC through a series of purchases of American Depositary Shares (ADS) on December 13th and 16th, 2024.

Summary

• Baker Bros. Advisors LP, along with affiliated entities, has reported the acquisition of additional American Depositary Shares (ADS) of Bicycle Therapeutics PLC.
• The transactions occurred on December 13th and December 16th, 2024, with purchases made at various weighted average prices.
• On December 13th, purchases were made at prices ranging from $13.32 to $14.00 per ADS.
• On December 16th, purchases were made at prices ranging from $15.11 to $15.49 per ADS.
• These purchases have increased the total indirect holdings of Baker Bros. and related parties to over 9.9 million ADS.
• The reporting entities include Baker Bros. Advisors LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, Felix J. Baker, and Julian C. Baker.
• The transactions were executed by 667, L.P. and Baker Brothers Life Sciences, L.P. (the Funds), with Baker Bros. Advisors LP acting as the investment advisor.
• Felix J. Baker, a director of Bicycle Therapeutics, is associated with these entities and may be deemed to have an indirect pecuniary interest in the shares.
• Julian C. Baker also has an indirect pecuniary interest due to his association with the Funds.

Sentiment

Score: 8

Explanation: The document indicates a significant increase in investment by a major investor, suggesting strong confidence in the company's future. The purchases at increasing prices further support a positive sentiment.

Positives

• The increased investment by Baker Bros. Advisors LP and related entities indicates confidence in Bicycle Therapeutics PLC.
• The purchases were made at increasing prices, suggesting a positive outlook on the company's future performance.
• The significant increase in holdings demonstrates a strong commitment from a major investor.

Risks

• The document does not explicitly state any risks, but the increased holdings could lead to increased influence by Baker Bros. Advisors LP.
• The document does not provide any information about the future performance of the company or the market.

Management Comments

• Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, is a director of Bicycle Therapeutics plc.
• The reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer.

Industry Context

This filing indicates a significant investment by a major healthcare-focused investment firm in a biotechnology company, which is a common trend in the industry. The increased stake suggests a positive outlook on the company's prospects within the competitive biotech landscape.

Comparison to Industry Standards

• The transactions are typical for institutional investors like Baker Bros. Advisors LP, who often accumulate shares in companies they believe have growth potential.
• The reported prices are within the range of typical market fluctuations for a company like Bicycle Therapeutics PLC.
• The level of detail provided in the SEC Form 4 is standard for reporting changes in beneficial ownership.

Stakeholder Impact

• The increased investment may positively impact shareholder confidence.
• The increased investment may positively impact the company's ability to raise capital in the future.

Key Dates

Keywords

Bicycle Therapeutics, Baker Bros. Advisors, American Depositary Shares, ADS, Share Purchase, Investment, Securities, Ownership, Transaction